Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vinorelbine + capecitabine
- Development stage
- Phase 3
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Vinorelbine + capecitabine is a combination chemotherapy regimen consisting of two small molecule antineoplastic agents. Vinorelbine is a semi-synthetic vinca alkaloid that inhibits microtubule assembly, thereby disrupting mitosis and leading to cell death. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), which interferes with DNA synthesis by inhibiting thymidylate synthase, resulting in impaired DNA replication and cell death. This combination has been studied for the treatment of metastatic breast cancer and other solid tumors, often as an oral regimen or with intravenous administration of vinorelbine[1][2].
- Other names
- capecitabine and vinorelbine
02
Targets
TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vinorelbine + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vinorelbine + capecitabine.